The European Medicines Agency (EMA) has recommended a restriction on the chikungunya vaccine, Ixchiq, for people aged over 65 amid safety concerns from serious adverse events, including two fatalities. Despite its earlier approval, the EMA's investigation found a possible link between the vaccine and severe complications, particularly in older populations which were underrepresented in clinical trials. The agency emphasized the need for caution, highlighting that a causal relationship between the vaccination and adverse events remains unconfirmed. Similar restrictions have been adopted by the FDA, albeit with a lower age limit of 60.
The EMA has recommended restricting the use of the chikungunya vaccine for individuals over 65 after serious adverse events were reported, raising safety concerns.
Despite initial approval a year ago, the EMA has identified serious adverse effects linked to the vaccine in older populations, prompting a temporary restriction.
Collection
[
|
...
]